SynCardia Facebook SynCardia Twitter SynCardia LInkedIn SynCardia Google Plus SynCardia Youtube

Press Release:

SynCardia Systems, Inc. Honored With the
2015 Medical Company of the Year Award
by Az Business Magazine

Az Business magazine’s 8th annual Healthcare Leadership Awards recognizes outstanding industry men, women, institutions and companies.

SynCardia was named the 2015 Medical Company of the Year during the Az Business magazine Healthcare Leadership Awards. SynCardia was named the 2015 Medical Company of the Year during the Az Business magazine Healthcare Leadership Awards. TUCSON, Ariz. – Apr. 14, 2015 – On April 9, SynCardia Systems, Inc. was honored with the 2015 Medical Company of the Year Award in the 8th annual Az Business magazine Healthcare Leadership Awards.

“The Healthcare Leadership Awards honors the women, men and institutions whose passion and innovation are saving lives, extending lives and improving the quality of our lives,” says Cheryl Green, publisher for AZ Big Media, which publishes Az Business magazine, Arizona’s largest business publication.

A panel of industry experts named finalists and award winners in 11 healthcare categories. SynCardia was one of three finalists in its category with the other finalists being Medtronic and Insys Therapeutics.

“Tucson and Arizona is the international headquarters for the first and only FDA, Health Canada and CE-mark approved Total Artificial Heart in the world,” says Michael P. Garippa, CEO and President of SynCardia. “From 1969 through 2014 there have been 1,458 implants of 13 different artificial heart designs. The SynCardia Total Artificial Heart and its direct predecessors account for 1,397 or 96% of all implants.”

Similar to a donor heart transplant, the SynCardia Total Artificial Heart is the only approved device that eliminates the source of end-stage biventricular heart failure in which the native heart’s two ventricles can no longer pump enough blood for a person to survive.

In the United States, the SynCardia Total Artificial Heart is approved as a bridge to donor heart transplant. In Europe, the 70cc and 50cc SynCardia Hearts are used as a bridge to a donor heart transplant and for destination therapy, also known as permanent use. Use of SynCardia Hearts for destination therapy varies by country.

SynCardia is conducting an FDA-approved clinical study on the effectiveness of the SynCardia Total Artificial Heart for use as destination therapy in the United States. 

SynCardia also has begun an FDA-approved clinical study for the use of its smaller, 50cc version of the SynCardia Total Artificial Heart as a bridge to donor heart transplant. Its size is intended for use by women, smaller men and many adolescents. 

CAUTION - The 70cc SynCardia Total Artificial Heart, when used for destination therapy, is an investigational device, limited by United States law to investigational use.
CAUTION - In the United States, the 50cc SynCardia temporary Total Artificial Heart is an investigational device, limited by United States law to investigational use.

###

About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the SynCardia Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.

Follow SynCardia: Facebook | Twitter | LinkedIn | Google+

SynCardia Contact:
Janelle Drumwright, jdrumwright@syncardia.com, (520) 547-7463

Search offcanvas